A microbial metabolite referred to as 3,4 dihydroxybenzoic acid, derived from dietary fiber, improved antitumor immunity in mice.
A compound made by intestine micro organism throughout the breakdown of dietary fiber might supply a option to strengthen most cancers immunotherapy. In mouse research, University of Michigan researchers turned that compound into an oral drug that helped T cells assault tumors extra successfully.
The work, printed in Nature Nanotechnology, facilities on 3,4-dihydroxybenzoic acid, or DHB, a pure microbial metabolite produced within the intestine.
The method is designed to handle a significant limitation of immune checkpoint blockade, a most cancers remedy that releases pure brakes on the immune system so T cells can acknowledge and destroy most cancers cells. Though checkpoint therapies have reworked most cancers immunotherapy, response charges amongst sufferers are sometimes low.
“Our intestine microbiome produces many helpful compounds that can be utilized for brand spanking new drug growth,” mentioned James Moon, Ph.D., John G. Searle Professor of Pharmaceutical Sciences and a member of Rogel Most cancers Middle.
“That is the primary time anybody has proven that pure microbial metabolites will be developed as a brand new oral formulation for immunotherapy.”
A intestine metabolite strengthened reminiscence T cells
One purpose checkpoint immunotherapy can cease working is that T cells steadily lose their capability to kill most cancers cells and cease dividing.
Searching for compounds which may counter that decline, the researchers screened a number of metabolites produced by intestine microbes and recognized DHB as a promising candidate. The compound is of course generated as intestinal micro organism break down dietary fiber.
The researchers discovered that DHB inspired T cells to become reminiscence T cells, which play a central function in most cancers immunotherapy. These cells can multiply quickly and assist drive antitumor immune responses.
A prodrug overcame poor absorption
Utilizing DHB straight posed one other problem. Naturally occurring compounds reminiscent of DHB are sometimes poorly absorbed and rapidly faraway from the physique.
To enhance supply, the researchers developed a prodrug type of DHB. They enclosed the compound in a protecting nanoemulsion shell and transformed it into an inactive precursor that turns into energetic after reaching its goal tissues.
“Our intestine microbiome produces many helpful compounds that can be utilized for brand spanking new drug growth,” mentioned James Moon, Ph.D., John G. Searle Professor of Pharmaceutical Sciences and a member of the Rogel Most cancers Middle.
Mixed remedy eradicated tumors in mice
The researchers examined the oral prodrug in mouse fashions of melanoma, colorectal most cancers, and breast most cancers.
When the animals obtained the prodrug along with immune checkpoint blockade remedy, their tumors had been eradicated. The mice additionally developed long-term immune reminiscence that would stop the tumors from returning.
DHB appeared to have results past checkpoint remedy as properly.
“We discovered that DHB additionally improved the efficacy of CAR T-cell therapies, which is extensively used to re-engineer a affected person’s personal immune cells to focus on most cancers,” Moon mentioned.
“We hope that our outcomes from mouse tumor fashions will even maintain true in human medical trials.”
The researchers are actually screening extra compounds that would improve immune system exercise. In addition they hope the nanomedicine formulation strategies developed for this work may ultimately show helpful for treating autoimmune illnesses.
Reference: “Oral nano-delivery of a intestine microbial metabolite enhances T cell stemness for most cancers immunotherapy” by Kai Han, Younger Seok Cho, Mariko Takahashi, Xingwu Zhou, Hannah E. Dobson, Kim Hutchings, Yuesong Wu, Youngseo Na, Fang Xie, Julia Crowther, Jinmei Wu, Jin Xu, Chuan Lee, Himani Jasewicz, Yujin Kim, Minal Nenwani, Olamide Animasahun, Fulei Wuchu, Anthony Andren, Harrison Wong, Emma Camp, Ziye Wan, Qi Wu, Li Zhang, Cheng Xu, Katherine Dong, Yao Xu, Anna Schwendeman, Grace Y. Chen, Yuying Xie, Costas A. Lyssiotis, Martin Clasby, Deepak Nagrath, Yu Leo Lei and James J. Moon, 10 August 2026, Nature Nanotechnology.
DOI: 10.1038/s41565-026-02235-9
This work was supported by NIH (R01DE030691, R01CA271799, R01NS122536, R01DE031951, P30CA046592, R01DE026728 and R01CA271369); Nationwide Pure Science Fund for Glorious Younger Scientists Fund Program (Abroad) of China; Nationwide Pure Science Basis of China (52473160); Venture Program of Jiangsu Key Laboratory of Drug Design and Optimization; China Pharmaceutical College (DDOZZ202301); Rogel Most cancers Middle; Forbes Scholar Award and NIH T32 coaching grant (T32GM145304)
Disclosure: Patent purposes for microbial metabolite prodrug-based oral formulation to enhance the efficacy of ICB have been filed with Moon, Han, Nagrath, Hutchings and Clasby as inventors. Moon declares monetary pursuits for board membership, as a paid guide, for analysis funding, and/or as an fairness holder in EVOQ Therapeutics, and Saros Therapeutics. Lyssiotis has consulted for Astellas Prescribed drugs, Odyssey Therapeutics, Third Rock Ventures and T-Knife Therapeutics and is an inventor on patents pertaining to Kras-regulated metabolic pathways, redox management pathways in pancreatic most cancers and concentrating on the GOT1-ME1 pathway as a therapeutic method (US patent quantity 2015126580-A1, 05/07/2015; US patent quantity 20190136238, 05/09/2019; worldwide patent quantity WO2013177426-A2, 04/23/2015)
By no means miss a breakthrough: Join the SciTechDaily newsletter.
Observe us on Google and Google News.
